FDA approves ViiV Healthcare’s Juluca for maintenance treatment of HIV-1

TAGS

ViiV Healthcare, a joint venture between GlaxoSmithKline (GSK), Pfizer, and Shionogi, has received approval from the U.S. Food and Drug Administration (FDA) for its two-drug regimen, , for the maintenance treatment of adults with virologically suppressed human immunodeficiency virus type 1 (HIV-1). This groundbreaking treatment, composed of 50mg and 25mg, is the first of its kind to be approved for use as a once-daily, single-pill regimen.

Criteria for Juluca’s Use

Juluca is specifically approved for adults with HIV-1 RNA levels under 50 copies per mL who have been on a stable antiretroviral (ART) regimen for at least six months, with no history of treatment failure and no known substitutions associated with resistance to any of the regimen’s components. This approval provides a significant new option for patients who are looking to maintain viral suppression with a simplified treatment regimen.

See also  Lupin ropes in Spiro Gavaris as US generics business president

Clinical Trial Insights and Efficacy

The FDA’s approval of Juluca was supported by the results from the phase 3 SWORD-1 and SWORD-2 trials, which involved 1,024 participants. These studies demonstrated that Juluca’s two-drug regimen was non-inferior in maintaining viral suppression at 48 weeks compared to traditional three- or four-drug regimens. The trials provided robust evidence that patients could maintain suppression with fewer drugs in their treatment regimen, potentially reducing drug-related toxicity.

See also  Outlook Therapeutics trims workforce by 23% to fund Lytenava launch

Expert Opinions and Comments

John Pottage, Chief Scientific and Medical Officer at ViiV Healthcare, emphasized the company’s dedication to minimizing medication load for patients: “Based on the fundamental principle that no one should have to take more medicines than necessary, ViiV Healthcare has put in place a comprehensive two-drug regimen research and development programme built around the characteristics of dolutegravir.”

Debra Birnkrant, Director of the FDA Center for Drug Evaluation and Research, Division of Antiviral Products, also commented on the approval, stating, “Limiting the number of drugs in any regimen can help reduce toxicity for patients.”

See also  Alnylam Pharmaceuticals completes patient enrollment for Phase 3 trial of givosiran in acute hepatic porphyrias

Implications for HIV Treatment Paradigm

This FDA approval marks a significant advancement in the treatment landscape for HIV, offering a promising new therapy option that aligns with modern treatment goals of reducing medication burden while maintaining efficacy. Juluca’s approval could influence future drug development and approval strategies, focusing on enhancing patient adherence and quality of life through regimen simplification.


Discover more from Business-News-Today.com

Subscribe to get the latest posts sent to your email.

CATEGORIES
TAGS
Share This